March 17, 2025
TOPLINE: Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. METHODOLOGY: Researchers conducted a randomized, […]